Hospital initiative shortens COVID-19 treatment delays - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Hospital initiative shortens COVID-19 treatment delays

  • By

  • Matthew Solan

  • October 22, 2026

  • 4 min

Share

Objective:

To assess changes in COVID-19 treatment timing and health care professionals’ knowledge, competence and confidence following a quality improvement initiative.

Approach:
  • : A quasi-experimental pre-post study conducted from December 2024 through June 2025 across 4 health care systems included chart audits of 150 hospitalized adults in each phase.
  • : Eligible patients were aged 18 years or older and had positive SARS-CoV-2 antigen or molecular tests. Most had mild-to-moderate COVID-19 and were at high risk for progression to severe disease.
  • : Initial audit-feedback sessions involved 90 health care professionals who reviewed baseline findings, received point-of-care resources and developed institutional action plans.
  • : Follow-up workshops involving 20 professionals occurred 2 to 5 months later. Chart audits and professional surveys evaluated practice changes and educational outcomes.
Key Findings:
  • Median time to treatment initiation decreased from 12 hours to 7 hours.
  • Guideline-concordant treatment was documented in 97% of patients before the intervention and 95% afterward.
  • Remdesivir monotherapy increased from 65% to 69%, while nirmatrelvir/ritonavir monotherapy decreased from 21% to 18%.
  • Among 63 baseline survey respondents, difficulty classifying illness severity (48%) and gaps in guideline knowledge (41%) were the most frequently cited barriers.
  • Researchers reported significant improvements in knowledge, competence and confidence. During initial sessions, correct identification that remdesivir could be used regardless of renal impairment, including dialysis, increased from 27% to 46%. Moderate-to-high confidence in differentiating therapies by safety and efficacy increased from 67% to 94%.
  • During follow-up sessions, correct recommendations of remdesivir for a patient receiving dialysis increased from 25% to 100%. High confidence in overcoming barriers to early treatment increased from 35% to 100%.
  • Action plans most often prioritized guideline awareness (71%) and institutional protocol updates (36%). These were also the most frequently reported successfully implemented actions at follow-up, at 40% and 30%, respectively.
  • Among 27 follow-up survey respondents, 70% reported improved hospital performance in identifying risk factors, selecting therapies and initiating treatment promptly.
Interpretation:

Treatment initiation occurred sooner after the initiative, while documented guideline concordance remained high. Educational sessions and institutional action plans addressed reported barriers involving severity classification and guideline knowledge. The pre-post design limits attribution of the observed changes solely to the intervention.

Limitations:
  • The study used a quasi-experimental pre-post design rather than a randomized comparison.
  • Follow-up workshops involved 20 professionals, while 27 completed follow-up surveys; these were distinct reported participation counts.
  • The article does not report whether improvements persisted beyond the follow-up period or provide clinical outcomes such as mortality or length of stay.
  • Although researchers described improvements as significant, the article does not provide P values or confidence intervals.
Conclusion:

The initiative was associated with shorter median time to COVID-19 treatment initiation and improvements in reported educational outcomes. Guideline-concordant treatment remained high, and participants reported implementing guideline-awareness efforts and protocol updates.

Sources:

Original Source(s)

Related Content